Regulating effect of Yiqi Yangyin Xiaoying Decoction on B cell activation in autoimmune thyroiditis model rats
LI Yang1,2 MU Yafeng3 ZUO Xinhe1,2,3 TIAN Man1,2▲ ZHAO Yong1,2
1.Thyroid Disease Clinic Center, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430070, China;
2.Thyroid Disease Clinic Center, Hubei Province Academy of Traditional Chinese Medicine, Hubei Province, Wuhan 430070, China;
3.the First Clinical College, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430061, China
Abstract：Objective To observe the regulating effect of Yiqi Yangyin Xiaoying Decoction on B lymphocyte activation in rats with autoimmune thyroiditis (AIT) model. Methods According to random number table method, 50 female SD rats at four-five weeks were divided into normal control group, model group, low, medium and high dose Yiqi Yangyin Xiaoying Decoction groups, with 10 rats in each group. The AIT model was made by subcutaneous injection of porcine thyroglobulin and feed with high iodine water. The low, medium and high dose Yiqi Yangyin Xiaoying Decoction groups were given 6, 12 and 24 g/kg solution of Yiqi Yangyin Xiaoying Decoction by gavage, respectively. Normal control group and model group were given the same amount of normal saline by gavage, intervention for six weeks. Serum levels of thyroid stimulating hormone (TSH), thyroid globulin antibody (TGAb), thyroid peroxidase antibody (TPOAb) and the concentration of serum B cell activating factor (BAFF) were determined by enzymy-linked immunosorbent assay. The expression level of interleukin-10 (IL-10) in thyroid tissues of rats was detected by immunohistochemistry. Results Compared with the normal control group, serum TSH, TGAb, TPOAb levels and BAFF level in model group were increased, while the expression level of IL-10 in thyroid tissue was decreased, and the differences were highly statistically significant (all P ＜ 0.05). Compared with model group, the concentrations of TSH, TgAb and TPOAb in the medium and high dose Yiqi Yangyin Xiaoying Decoction groups were decreased, and the differences were highly statistically significant (all P ＜ 0.01); the concentration of TGAb and TPOAb in low dose Yiqi Yangyin Xiaoying Decoction group were decreased, and the differences were highly statistically significant (P ＜ 0.01); BAFF content in all dose groups of Yiqi Yangyin Xiaoying Decoction decreased, and the relative expression level of IL-10 in thyroid tissue increased, and the differences were statistically significant (all P < 0.05). TSH concentrations in the medium and high dose Yiqi Yangyin Xiaoying Decoction groups were lower than those in the low dose Yiqi Yangyin Xiaoying Decoction group, and the differences were highly statistically significant (P ＜ 0.05 or P ＜ 0.01). The concentration of TGAb in the high dose Yiqi Yangyin Xiaoying Decoction group was lower than that in the medium and low dose Yiqi Yangyin Xiaoying Decoction groups, and that in the medium dose Yiqi Yangyin Xiaoying Decoction group was lower than that in the low dose Yiqi Yangyin Xiaoying Decoction group, and the differences were highly statistically significant (P ＜ 0.05 or P ＜ 0.01). The content of BAFF in the high dose Yiqi Yangyin Xiaoying Decoction group was lower than that in the low and medium dose Yiqi Yangyin Xiaoying Decoction groups, and the differences were statistically significant (all P ＜ 0.05). The expression level of IL-10 in the medium and high dose Yiqi Yangyin Xiaoying Decoction groups was higher than that in the low dose Yiqi Yangyin Xiaoying Decoction group, and the differences were statistically significant (all P ＜ 0.05). Conclusion Yiqi Yangyin Xiaoying Decoction decreases TSH, TGAb and TPOAb levels in AIT rats, and improves immune imbalance, which may be related to the mechanism of inhibiting B lymphocyte activation and upregulating thyroid IL-10 expression.
[1] 费宗奇，马朝群.许芝银教授治疗桥本甲状腺炎临床经验[J].现代中西医结合杂志，2019，28（10）：1076-1079.
[2] 陈银，魏军平.中医药治疗桥本氏甲状腺炎的临床研究进展[J].世界中西医结合杂志，2014（7）：789-792.
[3] 华川，陈如泉.芪箭消瘿汤对小鼠实验性自身免疫性甲状腺炎治疗作用的研究[J].湖南中医药导报，2003，9（4）：91-93.
[4] 牧亚峰.白芍总苷对自身免疫性甲状腺炎大鼠免疫调节机制的研究[D].武汉：湖北中医药大学，2018.
[5] 邓莉，孙文，侯毅，等.自身免疫性甲状腺炎实验动物模型的研究进展[J].天津中医药，2016，33（3）：189-192.
[6] 余欣然，向楠，李家园，等.白芍总苷胶囊对自身免疫性甲状腺炎模型大鼠Treg细胞的影响[J].云南中医学院学报，2017，40（6）：5-8.
[7] Posselt RT，Coelho VN，Skare TL. Hashimoto thyroiditis，anti-thyroid antibodies and systemic lupus erythematosus [J]. Int J Rheum Dis，2018，21（1）：186-193.
[8] Ferrari SM，Fallahi P，Elia G，et al. Novel therapies for thyroid autoimmune diseases：An update [J]. Best Pract Res Clin Endocrinol Metab，2020，34（1）：101366.
[9] 黄园园，刘亚楠，于世鹏.CD4+T淋巴细胞相关细胞因子与桥本氏甲状腺炎发病机制的研究进展[J].中华诊断学电子杂志，2019，7（3）：214-216.
[10] Cui X，Liu Y，Wang S，et al. Circulating Exosomes Activate Dendritic Cells and Induce Unbalanced CD4+T Cell Differentiation in Hashimoto Thyroiditis [J]. J Clin Endocrinol Metab，2019，104（10）：4607-4618.
[11] Ben-Skowronek I，Szewczyk L，Kulik-Rechberger B，et al. The differences in T and B cell subsets in thyroid of children with Graves’ disease and Hashimoto’s thyroiditis [J]. World J Pediatr，2013，9（3）：245-250.
[12] Rydzewska M，Jaromin M，Pasierowska IE，et al. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases [J]. Thyroid Res，2018，11：2.
[13] Kuklina EM，Smirnova EN，Nekrasova IV，et al. Role of B cells in presentation of autoantigens to CD4（+）T cells in patients with autoimmune thyroiditis [J]. Dokl Biol Sci，2015，464：263-266.
[14] Kristensen B，Hegedus L，Lundy SK，et al. Characterization of Regulatory B Cells in Graves’ Disease and Hashimoto’s Thyroiditis [J]. PLoS One，2015，10（5）：e127949.
[15] Lin JD，Wang YH，Fang WF，et al. Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease [J]. Clin Chim Acta，2016，462：96-102.
[16] Cheng CW，Tang KT，Fang WF，et al. Synchronized expressions of serum osteopontin and B cell-activating factor in autoimmune thyroid disease [J]. Eur J Clin Invest，2019，49（7）：e13122.
[17] Boonpiyathad T，Satitsuksanoa P，Akdis M，et al. IL-10 producing T and B cells in allergy [J]. Semin Immunol，2019，44：101326.
[18] Zhang ZL，Lin B，Yu LY，et al. Gene therapy of experimental autoimmune thyroiditis mice by in vivo administration of plasmid DNA coding for human interleukin-10 [J]. Acta Pharmacol Sin，2003，24（9）：885-890.
[19] Lei Y，Yang J，Li H，et al. Changes in glucose-lipid meta-bolism，insulin resistance，and inflammatory factors in patients with autoimmune thyroid disease [J]. J Clin Lab Anal，2019，33（7）：e22929.
[20] 李婵，孙勤国.益气养阴疏肝合剂通过Fas/FasL途径治疗大鼠桥本氏甲状腺炎[J].广州中医药大学学报，2020， 37（1）：134-139.
[21] 贾云丽，高燕明，卢桂芝，等.桥本甲状腺炎甲状腺组织中白细胞介素10的表达[J].北京医学，2002，24（5）：310-312.
[22] Rosser EC，Mauri C. Regulatory B cells：origin，phenotype，and function [J]. Immunity，2015，42（4）：607-612.
[23] Miyagaki T，Fujimoto M，Sato S. Regulatory B cells in human inflammatory and autoimmune diseases： from mouse models to clinical research [J]. Int Immunol，2015， 27（10）：495-504.
[24] Kristensen B. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls [J]. Dan Med J，2016，63（2）：B5177.
[25] Liu Y，Tang X，Tian J，et al. Th17/Treg cells imbalance and GITRL profile in patients with Hashimoto’s thyroiditis [J]. Int J Mol Sci，2014，15（12）：21674-21686.
[26] 张惠华，梁亚楠，张蕾.黄芪药学与临床研究现状分析[J].西部中医药，2020，33（12）：146-149.
[27] 王雪梅，贾天玉，管彬，等.黄芪多糖对免疫抑制模型小鼠Treg细胞及Th17细胞亚群的影响[J].天然产物研究与开发，2015，27（1）：153-157.
[28] 杜雪洋，梁建庆，何建成，等.黄芪多糖的药理作用研究[J].西部中医药，2019，32（6）：152-155.
[29] 童芳，刘辉，董群，等.白芍总苷对EAT小鼠Treg/Th17免疫平衡的影响[J].基础医学与临床，2019，39（8）：1157-1162.
[30] 曹拥军，蒋晟昰，罗燕萍，等.穿山龙对桥本甲状腺炎患者Th1/Th2型细胞因子表达的影响[J].中华中医药杂志，2016，31（3）：1103-1105.
2021, Vol. 18 
京公网安备 11010502046598号